Hypertriglyceridemia

In patients with prior MI from the REDUCE-IT cohort, icosapent ethyl reduced risk for first and total CV events compared with placebo, according to new data presented at the European Society of Cardiology Congress.

Sacubitril/valsartan drastically reduced triglycerides compared with valsartan in patients with HF with preserved ejection fraction, according to a presentation at the American College of Cardiology Scientific Session.

In a phase 2 study, evinacumab reduced triglyceride levels in patients with severe hypertriglyceridemia but not familial chylomicronemia syndrome, a speaker reported at the American College of Cardiology Scientific Session.

Omega-3 fatty acid supplementation was associated with elevated risk for atrial fibrillation among patients with elevated triglyceride levels at high CV risk, researchers reported.

Elevated maternal lipids, especially elevated levels of triglycerides, were associated with the development of gestational diabetes, according to new results from a systematic review and meta-analysis.

Improvements in CV outcomes from hypertriglyceridemia treatment with icosapent ethyl, compared with placebo, increased as daily levels of eicosapentaenoic acid increased, according to an analysis of the REDUCE-IT trial.

Omega-3 carboxylic acid (Epanova, Novartis) vs. corn-oil placebo in statin-treated, high CV-risk adults with elevated triglycerides.

In a new study, levels of triglycerides and remnant cholesterol — but not LDL or HDL — were associated with major CVD outcomes, independent of lifestyle and other risk factors, in older adults with high CV risk and overweight or obesity.

Administration of high-dose omega-3 carboxylic acid compared with corn oil placebo did not reduce incidence of major adverse CV events among statin-treated adults with elevated triglycerides at high CV risk.

Compared with placebo, icosapent ethyl reduced first and total MACE in patients with prior PCI, according to results from REDUCE-IT PCI presented at the virtual TCT Connect.